FDA Warns GLP-1 Drugs Carry Possible Rare Blindness Risk
WSJ Minute Briefing

FDA Warns GLP-1 Drugs Carry Possible Rare Blindness Risk

B2Upper-intermediateNovember 9, 20261 min
  • News bulletin
  • Business & money

Plus: Oil prices slide after President Trump suggests new strikes against Iran aren’t likely. And Children’s Place files for bankruptcy. Alex Ossola hosts. Sign up for WSJ’s free What’s News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Play episode

Opens the player: the full transcript, every word clickable, with translation and flashcards.

Try it: tap any word

Real sentences from the start of this episode. Every word is marked with its level.

Sentence 3 of 12 · 0:09

I'm Alex Ocela for The Wall Street Journal.

and Zepbound to warn about a rare eye condition that can cause permanent vision loss.

Hear this sentence

Tap a word to see its meaning in your language.

Do you know these words?

8 harder words from this episode. Tap one to see what it means, then mark it.

  • B20:09
  • C10:09
  • B20:18
  • C10:30
  • B20:47
  • B21:02
  • B21:20
  • B21:27

Mark a few words and we'll tell you how this episode fits your level.

Is this episode right for you?

B2

B2 · Upper-intermediate

Comfortable if you already follow TV news

A1 19%A2 25%B1 44%B2 13%C1 0%
  • 87% of the words are B1 or easier.
  • 174 words a minute: natural, fairly fast speech.
  • 17 harder words (B2 and up) in the whole episode.

Transcript

The opening of the episode. The whole transcript is in the player.

0:00

Here's your midday brief for Monday, November 9th. I'm Alex Ocela for The Wall Street Journal. Federal regulators are requiring makers of blockbuster weight loss drugs like Ozempic and Zepbound to warn about a rare eye condition that can cause permanent vision loss.

0:18

The FDA says a review of studies on patients taking GLP-1 medications found evidence of a potential increased risk of partial blindness. and Eli Lilly spokeswoman says the company is evaluating the FDA's update. Novo is working with regulators and says that it remains confident the benefits outweigh

0:34

the risks of its GLP1s. Lilly and Novo have previously said the studies don't prove that the medications caused the condition. Sanofi, which also has an approved GLP1 drug, didn't immediately respond to a request for

That was the opening. The rest of the episode (1 min) is in the player: every word clickable, with translation, saved words and flashcards.

Continue in the player

Automatically generated from the audio. May contain errors. Audio belongs to its publisher and is played from their feed. Rights holders can request removal — copyright & takedown policy